Preclinical Development of PEG-TNF

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44CA085023-02
Agency Tracking Number: CA085023
Amount: $808,828.00
Phase: Phase II
Program: SBIR
Awards Year: 2004
Solicitation Year: 2004
Solicitation Topic Code: N/A
Solicitation Number: PHS2004-2
Small Business Information
PHOENIX PHARMACOLOGICS, INC.
PHOENIX PHARMACOLOGICS, INC., ASTECC FACILITY #A-217, LEXINGTON, KY, 40506
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOHN Bomalaski
 (610) 524-7710
 JOHNSBOMALASKI@MSN.COM
Business Contact
 MIKE CLARK
Phone: (859) 257-9027
Email: MCLARK@PHOENIXPHARM.ORG
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemic administration of unformulated huTNFalpha has been te

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government